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Abstract
Painful diabetic neuropathy (PDN) is a condition prevalent in diabetic patients. As
the rate of diabetes mellitus (DM) continues to rise, so will the comorbid conditions
associated with it, such as PDN. This review will examine a patient, D.J., seen during
an OSCE exam, who was diagnosed with type two DM three years ago. He presents
to his primary care provider for a follow up, with concerns of elevated fasting blood
glucose levels. This review will further discuss the screening and periodic
monitoring that diabetic patients need every three to six months, in order to assess
for micro and macrovascular changes, including PDN. The prevalence of PDN is
increasing with the rising rates of diabetes, and can have damaging effects on the
patients who suffer from this condition. Furthermore, this review will discuss the
consensus recommendations for the treatment of PDN, through a literature review.
The literature review will specifically address treatment strategies for PDN with
duloxetine, a serotonin-norepinephrine reuptake inhibitor, and pregabalin, an
alpha-2-delta ligand agonist. Duloxetine and pregabalin have been shown to
effectively treat PDN with fewer side effects and adverse drug reactions when
compared to other treatment strategies. Duloxetine and pregabalin will be
compared to each other for their efficacy and their cost effectiveness.
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Background
This review will begin by discussing the case of D.J., a type two diabetic of
three years, who presents to his primary care provider with elevated fasting glucose
levels. Although this patient has no current overt micro or macrovascular changes
associated with his diabetes, it is vital to routinely screen for these comorbidities at
each patient encounter. D.J. is similar to many diabetic patients who have difficulty
controlling either their fasting blood glucose levels or their postprandial blood
glucose levels, or both. D.J. does not currently have peripheral neuropathy, as
evidenced by subjective reports and physical assessment; but he, like each diabetic
patient, is at risk for developing PDN. Elevated glucose levels are the main cause of
PDN, and research has proven that tighter glycemic control prevents and delays the
onset of PDN. Because of this, D.J.’s provider must continue to be diligent about
lowering his blood glucose levels while continuing to screen for PDN.
The prevalence of DM is rising rapidly in the United States and worldwide.
Currently, almost 30 million Americans are diagnosed with DM, with 95% of those
patients being type two diabetics. This number will likely rise, and by 2050, one in
three Americans will have a diagnosis of DM (American Diabetes Association [ADA],
2014). There are numerous micro and macrovascular changes that occur due to
elevated glucose levels in diabetics, including PDN. Providers must be persistent in
assessing for early signs of PDN during diabetic follow-up visits by completing
various assessments, including a complete foot exam. This is of utmost importance
because PDN is present in approximately 10-50% of diabetic patients (Peltier,
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Goutman, & Callaghan, 2014), and is often the first presenting symptom of DM in
type two diabetics. PDN can present insidiously and can be discovered by physical
exam, while other times PDN presents with significant pain and distressing
symptoms such as shooting pains, numbness, tingling, pins and needles sensations,
and burning pain, prompting the patient to see a provider. Decreasing a patient’s
fasting plasma glucose levels and decreasing hemoglobin A1c levels to a goal set
jointly by the patient and the provider are of utmost importance in the prevention of
PDN. Although many patients may attempt to control their serum glucose levels,
pharmacologic treatment for PDN will be necessary in many cases.
The treatment of PDN has evolved over the last decade, and likely will
continue to evolve as more patients are diagnosed with DM, and will consequently
suffer from PDN. There are multiple modalities providers can offer their patients for
the relief of PDN. This review will focus on two of the first-line agents: duloxetine
and pregabalin. Other agents exist for the treatment of PND, like tricyclic
antidepressants (TCAs) and opioids. However, due to their side effect profile TCAs
and opiates have fallen in superiority to serotonin and norepinephrine reuptake
inhibitors and alpha-2-delta ligand agonists, which have proven to be at least as
effective with fewer side effects.
Case Report
D.J. is a 65-year-old Caucasian male, who is assessed during an OSCE exam
for a recheck of his type two DM. He was encouraged by his diabetic nurse educator
to follow up with his primary care provider after reporting fasting blood glucose
levels consistently over 150 mg/dL for one month. He checks his fasting glucose
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approximately two to three mornings each week, and does not routinely check his
postprandial blood glucose. D.J. was diagnosed with type two DM three years ago, at
the age of 62, after months of fatigue, weight gain, and polydipsia. His initial A1c was
8.7%, and he initially underwent three months of medical nutrition therapy (MNT)
and increased exercise. With MNT and exercise, he was able to drop his A1c to 8.2%,
and at that time began on twice daily dosing of Metformin 500 mg. He has remained
on this dose of Metformin and spent time with a dietician to learn how to
incorporate carbohydrate counting into his diet. He has been following with his
primary care provider every three to six months, and his hemoglobin A1c has been
around 8% for the past year.
In addition to type two DM, D.J.’s past medical history includes hypertension,
hyperlipidemia, and coronary artery disease with two coronary stents placed in
2014. His medications include Metformin 500 mg twice daily, Plavix 75 mg daily,
Aspirin 81 mg daily, Lasix 20 mg daily, Lisinopril 20 mg daily, Atorvastatin 20 mg
daily, and a Multivitamin daily. Like many type two diabetic patients, D.J. struggles
with his weight and activity level. He works full time in an office setting and is
sedentary most of the day. His BMI at the time of his most recent clinic visit is 29.1,
which is elevated from 28 six months ago. Aside from his slight weight gain, and
elevated fasting glucose levels, his review of systems is otherwise negative. A
complete physical exam is also negative, including complete foot exam.
Although D.J. presents feeling well with a negative review of systems and
physical exam, his provider understands the importance of routine screening in the
diabetic population. At each clinic visit, D.J. has a comprehensive foot exam to assess
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for peripheral neuropathy. It is imperative that his provider continues to assess for
PDN, as it is known that between 10-50% of diabetic patients suffer from PDN
(Peltier, Goutman, & Callaghan, 2014). This comprehensive foot exam will include a
full inspection of his skin, pulse checks, capillary refill time, monofilament testing,
pinprick testing, and vibration testing with a 10-g tuning fork. In addition to his foot
exam, D.J. has not had fasting labs done for one year. Therefore, a fasting lipid panel,
complete blood count, basic metabolic panel, liver function tests, Hemoglobin A1c,
and Urinalysis were all completed in the clinic. His complete lab results are found in
the Appendix.
Notably, D.J.’s A1c has risen to 9.5%. Because of this change, he will increase
his Metformin dose to 1000 mg in the morning, and 500 mg at night for one week,
then increase again to a goal of 1000 mg twice daily. He will be meeting with a
Registered Dietician who specializes in DM to review carbohydrate counting and
plan for weight loss. He has agreed to join an exercise facility with the intention of
establishing with a physical trainer for an individualized exercise routine. Education
was provided to D.J. that glucose control is of utmost importance to prevent PDN,
and other end-organ damage. Although D.J. is not in need of treatment for PDN at
this time, multiple pharmacotherapeutic options exist for PDN, including serotoninnorepinephrine reuptake inhibitors, and alpha-2-delta ligand agonists, among other
options. The following sections of this review will discuss these options, with a focus
on two of the most frequently used agents: duloxetine, a serotonin-norepinephrine
reuptake inhibitor, and pregabalin, an alpha-2-delta ligand agonist. The efficacy,
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benefits, risks, and cost-effectiveness of duloxetine and pregabalin will be discussed
through a literature review.
Literature Review
As stated above, DM affects nearly 30 million Americans; if this trend
continues, DM will affect one in three Americans by 2050 (ADA, 2014). Patients
diagnosed with DM often have multiple comorbidities, including hypertension,
hyperlipidemia, coronary artery disease, retinopathy, and PDN. The patient
reviewed in the case study, D.J., has had relatively stable glucose control throughout
his diagnosis, and although he has multiple comorbidities, he has not experienced
PDN. While D.J. denies symptoms of PDN, it is imperative to continue screening him
at each clinic visit. The importance of continued surveillance of PDN is emphasized
by the prevalence of PDN in the diabetic population. Though reports vary, studies
have shown PDN to be present in between 10-50% of diabetic patients (Peltier,
Goutman, & Callaghan, 2014). Moreover, PDN is frequently detected at the time of
DM diagnosis for type two diabetics, and close to five years after the initial diagnosis
of type one diabetics.
Search Strategy
The author searched the CINAHL and PubMed databases for articles related
to duloxetine, pregabalin, and diabetic nerve pain, between the years of 2005 and
the present date. When searching for articles using the CINAHL database, the
keywords “diabetes mellitus” and “duloxetine” and “pregabalin” retrieved nine
articles. Search criteria included English language and peer-reviewed articles. The
MeSH database through PubMed was utilized to search for additional articles. Using
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the Boolean phrase “AND,” the MeSH terms “diabetic neuropathies” and “duloxetine
hydrochloride” and “pregabalin” with search filters “human” and “10 years” were
used and generated 32 additional articles.
Symptoms of Painful Diabetic Neuropathy
PDN causes many distressing and debilitating symptoms for the diabetic
patient. PDN can cause pain often described as stabbing, electric, burning, cold, or
sharp. These sensations may occur continuously or intermittently and often at night.
The patient with PDN may also experience hyperalgesia or allodynia, which may be
triggered by wind, clothing, heat, or cold (Attal, 2012). These symptoms are caused
by microvascular changes that produce damage to small nerve fibers. The
neuropathy causes a characteristic, symmetrical, stocking and glove sensory
impairment, which begins in the bilateral toes and fingers, and progresses
proximally in the extremities, not limited to a dermatome pattern (Peltier, Goutman,
& Callaghan, 2014).
In addition to causing significant pain and decreased sensation, PDN impairs
many other aspects of the patient’s life. Boyle et al. (2012) explain that PDN may
reduce the patient’s sleep, mental health, and affect of the patient’s activities of daily
living, consequently causing a decreased quality of life. Reduced quality of life, in
addition to continuous pain, not only leads to financial costs of treatments, but also
the financial cost from loss of productivity from these patients (Boyle et al., 2014).
Screening for Painful Diabetic Neuropathy
Due to the chronic nature and prevalence of PDN in diabetic patients, the
American Diabetes Association recommends initiating screening for PDN at the
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diagnosis of type two DM, and five years after the diagnosis of type one DM patients
(Cefalu, 2016). There are multiple tools available for the screening of PDN, though
the assessment of subjective reports of the patient’s history of pain qualities must
be completed first (Chong & Hester, 2007). Other objective screening methods,
approved by the American Diabetic Association, include the use of monofilament
testing and one or more of the following: Achilles tendon reflex, vibration
perception using a 128 Hz tuning fork, or pinprick sensation (Peltier, Goutman, &
Callaghan, 2014). Visual examination of the foot should occur at each clinician visit,
and the above-mentioned assessment techniques should be assessed at least
annually.
Another less-utilized method of screening for PDN frequently used in
research studies, is the Leeds Assessment of Neuropathic Symptoms and Signs,
which includes both subjective and objective assessments (Attal, 2012). For greater
specificity, used in clinical practice and research studies, nerve conduction studies
and biopsy of the hairy skin may be used. Though sensitivity and specificity are
increased, nerve conduction studies and biopsies are used less often due to the need
for an experienced technician as well as the cost (Peltier, Goutman, & Callaghan,
2014).
Treatment for Diabetic Neuropathy: Duloxetine
There have been many treatments and medications applied in the treatment
of PDN; however, this literature review will focus on the efficacy and costeffectiveness of two of the FDA approved medications: duloxetine and pregabalin.
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Duloxetine is a serotonin and norepinephrine reuptake inhibitor that was
first approved by the US Food and Drug Administration for the use in PDN in
September 2004 (Wernicke et al., 2006). Tanenberg et al. (2011) explain that “by
inhibiting the reuptake of norepinephrine and serotonin, duloxetine increases the
levels of these neurotransmitters in the central nervous system” (p. 615),
consequently reducing the perception of pain.
As for the efficacy in PDN pain reduction, duloxetine has shown good results.
In a study by Boyle et al. (2012) the authors compared the effects of duloxetine, in
the reduction of pain compared with placebo. Duloxetine was shown to have a
greater reduction in pain levels when compared with placebo. In addition, the study
assessed sleep continuity and quality. Although duloxetine showed benefits with
pain levels, there was a significant effect on the patient’s sleep continuity compared
to placebo, and also compared to patients who were placed on pregabalin and
amitriptyline. The study found a reduced total sleep time, as well as an increased
wake time after sleep onset with duloxetine (Boyle et al., 2006).
In a review by Peltier, Goutman, and Callaghan (2014) the authors
discovered a consistent improvement in PDN pain reduction with the use of SNRIs
like duloxetine, especially when compared to older antidepressants used previously
that have more side effects. They found that duloxetine has shown a reliable “NNT
[number needed to treat] between 2.1 and 5.5 to maintain a 50% pain reduction”
(Peltier, Goutman, & Callaghan, 2014, p. 5). Although duloxetine is not without side
effects such as disturbed sleep, there are benefits to using an SNRI for PDN. Peltier,
Goutman, and Callaghan (2014) point out that for patients who need
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pharmacotherapeutics for anxiety and depression, duloxetine may offer the benefit
of dual therapy for their pain relief and treatment for mental health conditions.
Similarly, a study by Wernicke et al. (2006) found efficacy in the treatment of
PDN with duloxetine, both at 60 mg daily and 60 mg twice daily dosing through a
12-week trial, when compared to placebo. Although both dosing parameters were
found to be effective in reducing PDN, the 60 mg twice daily dosing was continued
for a 52-week extension trial versus placebo, due to slightly better efficacy when
compared to the once daily dosing. Results of the 52-week study showed significant
improvement in PDN, as well as quality of life as measured by the SF-36 (a short
form health survey), for the patient randomized to the duloxetine 60 mg twice-daily
group as compared to placebo. Adverse effects of duloxetine were found in the
study, including a slightly increased fasting blood glucose level and a slightly
increased LDL level; however, both of these findings were not statistically
significant, and would need to be further studied to be conclusive (Wernicke et al.,
2006).
A study by Chong and Hester (2007) compared various treatment options for
PDN, including duloxetine, pregabalin, narcotic pain medications, and tricyclic
antidepressants. The authors found promising results with duloxetine when
comparing three large randomized control trials. The NNT for 60 mg daily of
duloxetine was 4.3, while the NNT for 60 mg twice daily of duloxetine was 3.8, with
the result of 50% pain relief, with a 95% confidence interval (Chong & Hester,
2007). Although narcotic pain medications revealed slightly better pain control
when compared to duloxetine, the authors noted the fact that opiates bring a high
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risk of addiction, adverse effects, and tolerance issues when compared to
duloxetine.
In a study by Tanenberg et al. (2011) the authors completed a noninferiority
study, assessing whether patients would receive as good of pain control when
switching from gabapentin to duloxetine 60 mg daily, as they do while switching
from gabapentin to pregabalin 300 mg daily. Patients’ pain was measured using a
Likert scale and assessed the reduction in weekly pain mean at baseline compared
to the end of 12 weeks. The study concluded that duloxetine was noninferior to
pregabalin for the reduction in PDN, with an estimated -2.6 change in daily pain
score after 12 weeks with duloxetine, as opposed to a -2.1 change with pregabalin
(Tanenberg et al., 2011). Interestingly, duloxetine was found to have better pain
reduction versus pregabalin at week 2, 3, and 5 through 11, but at week 12 the
results were not statistically significant, with both drugs showing good results.
Treatment for Diabetic Neuropathy: Pregabalin
Pregabalin is an alpha-2-delta ligand agonist, approved by the FDA in 2004
for the treatment of PDN. Attal (2012) explains that pregabalin works by
“decreasing the central sensitization and nociceptive transmission through their
action on the alpha-2-delta subunit of calcium channels” (p. 163). Pregabalin is a
first line recommendation for PDN from the American Academy of Neurology, and
multiple studies have shown its efficacy.
A randomized withdrawal trial by Raskin et al. (2014) looked at the efficacy
of pregabalin versus placebo for the treatment of PDN after other therapeutic
mechanisms had failed. At the end of this 19-week trial, the 125 people randomized
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to the pregabalin group displayed a decrease in mean pain scores from 6.8 at the
beginning of the trial to 2.9 at the end of the trial. In comparison, the placebo group
decreased from a mean pain score of 6.7 to 3.2 at the end of the trial. Although
results were similar and not statistically significant at the end of the 19-week trial
compared to placebo, the mean pain scores at week 7 and 18 were in fact
statistically significant in favor of pregabalin (Raskin et al., 2014). This is important
to note, because pregabalin did show faster pain response, as compared to a gradual
response to placebo. Lastly, it is important to point out two other factors found in
the study which are significant to clinical practice: quality of life and sleep. In both
categories, pregabalin showed statistically significant improvement in both quality
of life and sleep when compared to placebo (Raskin et al., 2014). These two factors
are often sought out from patients suffering from PDN.
Boyle et al. (2012) completed a double-blind, randomized control trial
looking at the effects of amitriptyline, duloxetine, and pregabalin in patients with
PDN. Each of the three drugs showed positive outcomes in pain reduction when
compared to placebo; however, no one drug showed higher statistical significance in
that respect. Although pain control was relatively similar across the board,
pregabalin did show greater efficacy in other aspects of the trial including quality of
life and sleep. Patients randomized to the pregabalin arm of the trial showed
improved ability getting to sleep and improved quality of sleep. This may be a
significant finding clinically, as pain control is often linked to fatigue and quality of
sleep. Although sleep was improved, pregabalin was shown to be inferior to
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duloxetine when it came to daytime sleepiness and concentration (Boyle et al.,
2012).
In a review of PDN by McKeage (2007), pregabalin was shown to be
efficacious in pain reduction with various doses. At the end of a 16-week trial,
pregabalin 75 mg twice daily reduced mean pain scores from 6.5 to 4.9. While at the
end of an eight week trial, pregabalin 150 mg twice daily reduced mean scores from
a baseline of 6.5 to an end point of 4.0. These were compared to placebo, and found
to be statistically significant. Although pregabalin was noted to be effective, the
author did comment that tolerability was important to be aware of with pregabalin,
with side effects including nausea, dizziness, somnolence, and fatigue. Yet, these
same side effects were dually noted for duloxetine therapy (McKeage, 2007).
Chong and Hester (2007) reviewed various treatment options for PDN,
including pregabalin. They examined a number of randomized placebo-controlled
trials with at least 50 participants. Their review assessed the NNT for a minimum of
50% pain reduction valued with a confidence interval of 95%. Pregabalin dosed at
150 mg twice daily was shown to have a NNT of 3.9 in a study with 146 patients,
while pregabalin dosed at 300 mg twice daily had even better results at NNT 3.3 in a
study of 338 patients (Chong & Hester, 2007). The authors note that there are
adverse effects associated with pregabalin, especially with rapid titration, including
peripheral edema, euphoric mood, dizziness, and drowsiness. Cerebral edema and
encephalopathy may occur when rapidly withdrawn, as well. Although these side
effects can be severe, the authors note that this drug is extensively studied and
efficacious, and best used when titrated slowly (Chong & Hester, 2007).
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Tanenberg et al. (2011) undertook a study to determine whether switching
from gabapentin to duloxetine 60 mg daily or pregabalin 150 mg twice daily
provided superior pain control with suboptimal control on the gabapentin.
Specifically, the study was looking at the noninferiority of duloxetine compared to
pregabalin. The study concluded that duloxetine was, in fact, noninferior to
pregabalin. Duloxetine showed even better pain control at weeks 2, 3, and 5 through
11, of this 12-week study. However, at week 12 pregabalin and duloxetine showed
results that were not statistically different. This may suggest that although
duloxetine may have a faster onset of action, pregabalin is just as effective as
duloxetine after 12 weeks (Tanenberg et al., 2011).
A study by Razazian, Baziyar, Moradian, Afshari, Bostani, and Mahmoodi
(2014) reviewed the effectiveness of pregabalin compared to carbamazepime, an
anti-epileptic, and venlafaxine, a serotonin and norepinephrine reuptake inhibitor,
similar to duloxetine. The study randomized 257 participants to the three groups
and ultimately found pregabalin to be more effective than the other two drugs
noted. Pregabalin’s NNT was found to be 4.0, for a 50% or greater reduction in PDN.
In a meta-analysis by Zhang et al. (2015), the authors reviewed nine trials
with a total of 2056 participants looking at the efficacy and safety of pregabalin.
Similar to other trials reviewed, the authors found that pregabalin was indeed
effective in reducing pain from PDN by at least 50%. Benefits and side effects of
pregabalin were noted and were similar to other trials, including the benefit of
improved sleep with pregabalin. Somnolence and dizziness were significantly worse
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for the participants taking pregabalin, and were found to be worse with higher
doses, including at 300 mg twice daily (Zhang et al., 2015).
Comparing Duloxetine and Pregabalin
After reviewing multiple studies, it would suffice to say that both duloxetine
and pregabalin are beneficial for the treatment of PDN. Each drug has their benefits,
risks, and side effects, making it crucial to look at each individual patient’s
circumstances prior to initiating a medication. For example, duloxetine is an
antidepressant and anxiolytic medication, making it a potentially better option for a
patient in need of therapy for PDN and depression and anxiety. Similarly, if a patient
were already established on a serotonin-enhancing medication, the provider would
not want to further reduce the reuptake of serotonin, for risk of serotonin
syndrome, thus making pregabalin a better option.
Furthermore, each drug has potential side effects that must be reviewed with
the patient in order to make an informed decision. Pregabalin has been shown to be
associated with improved sleep when compared to duloxetine (Attal, 2012), and
many patients greatly value improved sleep, accordingly improving their quality of
life. Yet, pregabalin may cause daytime somnolence or dizziness, making this a less
appealing choice for some patients in need of vigilance during the day. Other side
effects associated with pregabalin include peripheral edema, weight gain, euphoria,
headache, and dry mouth. Duloxetine is associated with side effects including
nausea, dry mouth, constipation, low appetite, sedation, and dizziness (Attal, 2012).
The presence of these side effects will depend on each individual patient, and also
may be minimized by slow titration and avoiding rapid initiation or withdrawal.
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Cost Effectiveness
Although the benefits and side effects of each medication are integral to
patient care, the cost of the medication is a major factor as to whether the
medication will work for each patient. According to UptoDate (2016) a 30-day
supply of 60 mg duloxetine hcl tablets is $235.29. Instead, pregabalin will not be
generic in the United States until 2018 and currently costs $621.05 for a 90-tablet
supply of 150 mg tablets (UpToDate, 2016). Individual insurance coverage will vary
among patients, but it is crucial to be aware of the high costs for patients, which may
tempt patients to inconsistently take their medications due to high out of pocket
costs, which may lead to suboptimal symptom control.
Conclusion
In conclusion, this review is meant to discuss the treatment options for the
growing problem of PDN in diabetic patients. This growth will likely parallel the
growth of DM, which is expected to be present in one in three Americans by 2050
(ADA, 2014). Although the patient in the case study, D.J., was not yet experiencing
PDN, there is a high likelihood that he will encounter this comorbidity during his
lifetime and treatment of DM. Because of this likelihood, it is imperative for
providers to continue to follow the ADA recommendations for screening for PDN at
each diabetic encounter using the methods suggested by the ADA.
The purpose of the literature review was to highlight and compare two of the
FDA approved treatments for PDN, duloxetine and pregabalin. As seen in the
literature review, there were few examples of trials comparing the efficacy of the
two drugs exclusively, but many trials were examined comparing each drug to
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placebo, and to multiple other drugs. Because of this, it is difficult to conclude
superiority of one drug over the other. Instead, it was found that each drug was
efficacious and safe compared to placebo for treatment of PDN in all trials reviewed.
The choice between duloxetine and pregabalin for the treatment of PDN must be a
joint decision between patient and provider, and include the discussion of
comorbidities, polypharmacy, and benefits and risks of the medications.
Furthermore, the cost of the medications for the patient must be considered before
prescribing one of the two treatment options, as this may be a large burden on the
patient.
Clinical Take Away
After reading this review, the reader should be able to communicate the
following points, and relate these themes to clinical practice.
•

PDN will be a growing problem seen in the clinical setting, with the
increasing rates of DM. Ongoing screening and assessment for PDN is
imperative for DM patients in order to reduce and avoid unnecessary
physical and financial burden. Screening for PDN should take place no later
than five years after the onset of type one DM, and at the initial diagnosis of
type two DM. Screening shall continue at each clinical encounter and include
subjective patient reports, as well as ADA-recommended screening methods.

•

Duloxetine and pregabalin are FDA approved for the treatment of PDN, and
have shown efficacy and safety in their reduction of PDN. Each drug has its
benefits and risks; thus, the initiation of one of the medications needs to
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include joint decision making between the patient and the provider and
consider the patient’s comorbidities and tolerance of the medication.
•

Cost effectiveness is crucial for the patient in the treatment of PDN. Providers
must keep in mind that the chosen drug will not be effective for PDN if the
patient is not taking the medication due to cost constraints.
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Appendix
Fasting Lab Results for D.J.
CBC

Reference Range Result

WBC

3.6 - 11.0 K/uL

8.92

RBC

3.8-5.2 M/uL

5.04

Hgb

12.0-16.0 g/dL

12.5

Hct

35-47%

42.5

MCV

80-100 fL

85.4

MCH

26-34 pg

23.3 (L)

MCHC

32-36 g/dL

28.2 (L)

RDW

37-50 fL

52.8 (H)

Platelets 150-440 K/uL

351

MPV

8.0-13.0 fL

9.4

nRBC

0.0-0.2/100WBC

0.0

BMP

Reference Range Result

Serum BUN

7-22 mg/dL

22

Sodium

136-145 mmol/L

139

Potassium

3.6-5.5 mmol/L

3.9

Chloride

98-109 mmol/L

102
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CO2

23-33 mmol/L

27.3

Serum Glucose

70-99 mg/dL

151 (H)

Serum Creatinine

0.6-1.3 mg/dL

1.3

Calcium

8.8-10.5 mg/dL

9.8

Anion Gap

5-13 mmol/L

9.7

GFR Calculated

>60 ml/min

49 (L)

Serum Albumin

3.4-4.7 g/dL

4.00

Alkaline Phosphatase 50-136 U/L

88

Total Protein

5.9-7.6 g/dL

7.4

Urinalysis

Reference Range Results

Urine Color

No range

Light Yellow

Urine Specific Gravity 1.003-1.03

1.012

Urine Glucose

Negative

Negative

Urine Ketones

Negative

Negative

Urine Hemoglobin

Negative

Negative

Urine Nitrite

Negative

Negative

Urine Leukocyte

Negative

Negative

Urine pH

5.0-8.0

7.0

Urine Total Protein

Negative

<300

Urine Bilirubin

Negative

Negative

Urine RBCs

#/HPF

2.6
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Urine WBCs

#/HPF

1.2

Urine Bacteria

#/HPF

32.2

Urine Epithelial Cells

#/HPF

0.5

Hyaline Casts

0.00-5.00/LPf

0.41

Turbidity UA

Clear

Clear

LFTs

Reference Range Result

Serum Albumin

3.4-4.7 g/dL

4.00

Alkaline Phosphatase 50-136 U/L

88

Total Bilirubin

0.2-1.2 mg/dL

0.4

AST

5-34 U/L

20

ALT

7-55 U/L

22

Total Protein

5.9-7.6 g/dL

7.4

Lipid Panel

Reference Range Result

Cholesterol

<200 mg/dL

199

Triglycerides <160 mg/dL

231 (H)

HDL

>40 mg/dL

38 (L)

LDL

<100 mg/dL

95
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